Experimental Treatment for Cryopyrin-Associated Periodic Syndrome (CAPS) Shows Potential in Early Trial
source: pixabay.com

Experimental Treatment for Cryopyrin-Associated Periodic Syndrome (CAPS) Shows Potential in Early Trial

According to a story from Financial Buzz, the biotechnology company Inflazome recently announced that it has completed a phase 1 clinical trial. This trial was testing the company's experimental treatment…

Continue Reading Experimental Treatment for Cryopyrin-Associated Periodic Syndrome (CAPS) Shows Potential in Early Trial

Extremely Positive Results from Systemic Juvenile Idiopathic Arthritis 5-year Follow-Up Study in the EU

Extremely positive results have just been announced from a 5-year follow-up study of a systemic juvenile idiopathic arthritis (sJIA) treatment called Kineret. This treatment has been approved for use in…

Continue Reading Extremely Positive Results from Systemic Juvenile Idiopathic Arthritis 5-year Follow-Up Study in the EU
Drug Label Expanded in the UK for Treating Rare Inflammatory Diseases
byrev / Pixabay

Drug Label Expanded in the UK for Treating Rare Inflammatory Diseases

According to a story from Hospital Healthcare Europe, The European Medicines Agency approved Kineret last year, an anti-inflammatory drug developed by Sobi. In the UK, Kineret is an approved treatment…

Continue Reading Drug Label Expanded in the UK for Treating Rare Inflammatory Diseases
A Drug for Still’s Disease Has Been Approved in Europe
Source: Pixabay

A Drug for Still’s Disease Has Been Approved in Europe

A drug called Kineret has been approved by the European Commission in 28 European countries for the treatment of both adult-onset and juvenile-onset Still’s disease, reports Check Orphan. Still’s disease…

Continue Reading A Drug for Still’s Disease Has Been Approved in Europe
Close Menu